Ivabradyna Synthon

Ivabradine, the active ingredient in Ivabradyna Synthon, is a If channel inhibitor presented as an oral dosage form for oral use. It lowers heart rate without affecting myocardial contractility and is indicated for chronic stable angina pectoris and heart failure with reduced ejection fraction.

GNH USA supplies Ivabradyna Synthon as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution. Customer support is available to address regulatory and technical inquiries.

Ivabradyna Synthon, an If channel inhibitor, is used in cardiovascular conditions where heart‑rate reduction improves outcomes, particularly in patients with angina or systolic heart failure.

- Chronic stable angina pectoris: lowers heart rate, which reduces myocardial oxygen demand and consequently decreases the frequency and severity of angina attacks. - Heart failure with reduced ejection fraction: decreases heart rate, improving ventricular filling time and reducing symptoms such as dyspnoea, while potentially lowering hospitalisation risk. - Exercise tolerance in angina patients: by controlling heart rate, patients can sustain physical activity longer before experiencing chest discomfort.

Ivabradyna Synthon may cause a range of adverse reactions, which are categorised by frequency and severity.

Common Side Effects: - Bradycardia: abnormally slow heart rate, often asymptomatic. - Visual disturbances (phosphen